Teva Pharmaceutical is the world's largest generic pharmaceutical company and one of the world's leading biotechnology companies.

Teva Pharmaceutical is the world's largest generic pharmaceutical company, with approximately $17 billion in annual revenue and commercial operations in approximately 60 countries. Teva's generic drug portfolio encompasses over 3,500 products — the broadest generic portfolio of any company globally — providing the medicines that make healthcare systems financially sustainable. Beyond generics, Teva's innovative portfolio includes AUSTEDO (deutetrabenazine) for tardive dyskinesia and Huntington's disease chorea, AJOVY (fremanezumab) for migraine prevention, and UZEDY (risperidone) for schizophrenia. Teva's Pivot to Growth strategy — focusing on innovative portfolio growth, biosimilar development, and operational efficiency — is generating its second consecutive year of revenue growth after years of financial restructuring.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management